REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors


10/09/2025 16:27:43

Primary registry identifying number	Protocol number
_BCTR2019010185	CABL001A2301
MOH registration number	
49983/2017	
Study registered at the country of origin	Study registered at the country of origin: Specify
Yes	
Type of registration	Type of registration: Justify
Retrospective	LCTR was already initiated, original file was previously submitted
Date of registration in national regulatory	
agency 21/12/2017	
Primary sponsor	Primary sponsor: Country of origin
Novartis Pharma Services Inc.	Novartis Pharmaceuticals
Date of registration in primary registry	Date of registration in national regulatory agency
30/01/2019	21/12/2017
Public title	Acronym
A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors	ASCEMBL
Scientific title	Acronym
A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors	
Brief summary of the study: English	
The purpose of this pivotal study is to compare the efficacy of ABL001 with that of bosutinib in the treatment of patients with CML- CP having previously been treated with a minimum of two prior ATP ⋅binding site TKIs with BCR-ABL ratios ≥ 1% IS at screening.	
Brief summary of the study: Arabic	
ب لدى المرضى ABL001 مفتوحة اللصاقة، متعددة المراكز حول دواء3دراسة جزافيّة في المرحلة ن بسرطان الدم النقوي المزمن في المرحلة المزمنة، المعالجين سابعًا بمثبّطيّن أو أكثر لكيناز التيروزيز	
Health conditions/problem studied: Specify	
Chronic Myelogenous Leukemia	

ABL001. Bosutinib

 \sim

REPUBLIC OF LEBANON Lebanon Clinical Trials Registry



• QTcF at screening ≥450 msec (male patients), ≥460 msec (female patients)

MINISTRY OF PUBLIC HEALTH

Male or female patients with a diagnosis of CML-CP ≥ 18 years of age

•< 30% blasts plus promyelocytes in peripheral blood and bone marrow</p>

Patients must meet all of the following laboratory values at the screening visit:

•Transient prior therapy related thrombocytopenia (< 50,000/mm3 for ≤ 30 days prior to screening) is acceptable

Prior treatment with a minimum of 2 prior ATP-binding site TKIs (i.e. imatinib, nilotinib, dasatinib, radotinib or ponatinib)

•No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly

BCR-ABL1 ratio ≥ 1% IS according to central laboratory at the screening examination

Key inclusion and exclusion criteria: Inclusion criteria

•< 15% blasts in peripheral blood and bone marrow</p>

< 20% basophils in the peripheral blood •≥ 50 x 109/L (≥ 50,000/mm3) platelets

· Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:

Risk factors for Torsades de Pointes (TdP)

· Concomitant medication(s) with a known risk of Torsades de Pointes per www.qtdrugs.org that cannot be discontinued or replaced 7 days prior to starting study drug by safe alternative medication.

- Inability to determine the QTcF interval
- · Severe and/or uncontrolled concurrent medical disease
- · History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis
- · History of acute or chronic liver disease
- Treatment with medications that meet one of the following criteria and that cannot be discontinued at least one week prior to the start of
- treatment with study treatment
- Moderate or strong inducers of CYP3A Moderate or strong inhibitors of CYP3A and/or P-gp

• Women of child-bearing potential, unless they are using highly effective methods of contraception during dosing and for 3 days after last dose of ABL001.

 Sexually active males unless they use a condom during intercourse while taking the drug during treatment and for 3 days after stopping treatment and should not father a child in this period. A condom is required to be used also by vasectomized men as well as during intercourse with a male partner in order to prevent delivery of the drug via semen.

Type of study

Interventional

Type of intervention

Pharmaceutical

Type of intervention: Specify type

N/A

REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

Trial scope Therapy	Trial scope: Specify scope N/A
Study design: Allocation Randomized controlled trial	Study design: Masking Open (masking not used)
Study design: Control Active	Study phase 3
Study design: Purpose Treatment	Study design: Specify purpose N/A
Study design: Assignment Other	Study design: Specify assignment 2:1
IMP has market authorization No	IMP has market authorization: Specify
Name of IMP ABL001	Year of authorization Month of authorization
Type of IMP Cell therapy	
Pharmaceutical class orally bioavailable specific BCR-ABL inhibitor with a novel mechanism of ac	tion.
Therapeutic indication patients with Chronic Myelogenous Leukemia-CP who had prior treatment v binding site TKIs	vith two or more ATP
Therapeutic benefit increase OS & PFS	
Study model N/A	Study model: Explain model N/A
Study model: Specify model N/A	
Time perspective N/A Time perspective: Specify perspective N/A	Time perspective: Explain time perspective N/A
Target follow-up duration	Target follow-up duration: Unit
Number of groups/cohorts	
Biospecimen retention	Biospecimen description



REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

Samples without DNA	Bone marrow aspirate samples, Hematology , chemistry , coagulation, hepatitis , Liver function tests , are sent to Covance central laboratory, Navigate biopharma, molecular MD and Histogene X .
Target sample size	Actual enrollment target size
5	1
Date of first enrollment: Type	Date of first enrollment: Date
Actual	05/09/2018
Date of study closure: Type	Date of study closure: Date
Actual	21/12/2022
Recruitment status	Recruitment status: Specify
Recruiting	
Date of completion	
29/02/2020	
29/02/2020 IPD sharing statement plan	IPD sharing statement description
	IPD sharing statement description Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
IPD sharing statement plan	Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with

Admin comments

Trial status

Approved

Secondary Identifying Numbers		
Full name of issuing authority	Secondary identifying number	
Clinical Trials.Gov	NCT03106779	

Sources of Monetary or Material Support

Name

Novartis Pharma Services Inc.



Secondary Sponsors

Name

NA

Contact for Public/Scientific Queries						
Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Ali Bazarbachi	Beirut	Lebanon	009613612 434	bazarbac@aub.e du.lb	American University of Beirut Medical Center
Scientific	Hind Khairallah	Beirut	Lebanon	+961 1 512002 Ext. 271	Hind.Khairallah@ fattal.com.lb	Khalil Fattal et Fils s.a.l.
Public	Joseph Kattan	Beirut	Lebanon	009613635 913	jkattan62@hotm ail.com	Hotel Dieu De France
Public	Dany ABi Gerges	Mansourieh	Lebanon	009613341 960	abgerges@idm.n et.lb	Bellevue Medical Center

Centers/Hospitals Involved in the Study			
Center/Hospital name Name of principles investigator Principles investigator speciality Ethical approva			Ethical approval
Bellevue Medical Center	Dr Dany Abi Gerges	Hematology Oncology	Approved
American University of Beirut Medical Center	Dr. Ali Bazarbachi	Hematology Oncology	Approved
Hotel Dieu De France	Dr Joseph Kattan	Hematology Oncology	Approved

Ethics Review				
Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
American University of Beirut Medical Center	05/06/2018	Fuad Ziyadeh	fz05@aub.edu.lb	+961 (0) 1 350 000 ext:5445
Hotel Dieu de France	02/10/2017	Nancy Alam	nancy.alam@usj.edu.lb	+961 1421000 ext 2335
Bellevue Medical Center	23/11/2017	Ghassan Maalouf	gmaalouf@bmc.com.lb	+961 1 682666 ext 7600





Countries of Recruitment
Name
Lebanon
Argentina
Australia
Belgium
Bulgaria
Canada
Czech Republic
France
Germany
Hungary
Italy
Japan
Republic of Korea
Netherlands
Turkey
United States of America
Saudi Arabia
United Kingdom

Health Conditions or Problems Studied		
Condition Code Keyword		
Chronic Myelogenous Leukemia	Leukaemia, unspecified (C95.9)	CML





Interventions			
Intervention	Description	Keyword	
Physical examination, Vital Sign, Height and weight, ECOG performance status, Laboratory chemistry and hematology, Serology, Electrocardiogram (ECG), Echocardiogram, Pulmonary function tests, PK sampling (full/sparse), Bone Marrow Biopsy, Patient Report Outcomes (MDASI-CML, PGIC, WPAI, EQ5D-5L, resource	ICF, Lab tests, physical examination, ECG	Lab, ECG, ICF, BMA	

Primary Outcomes		
Name	Time Points	Measure
Major Molecular Response (MMR) rate	24 weeks	24 wks

Key Secondary Outcomes			
Name	Time Points	Measure	
Major Molecular Response (MMR) rate	96 weeks after the last patient received the first study dose	96 weeks after first dose	
Complete Cytogenetic response rate	24,48,96 weeks	24,48,96 weeks	



Trial Results Summary results Study results globally Date of posting of results summaries Date of first journal publication of results Results URL link Baseline characteristics Participant flow Adverse events Outcome measures URL to protocol files